Medtronic's MiniMed Separation Enters Pricing Phase as Four Regulatory Milestones Land

Medtronic's MiniMed exchange offer pricing runs Oct 5-7, while the company adds FDA and CE clearances and new CPT codes for two therapies.

Medtronic is steering through a stretch that combines corporate restructuring with a wave of product and reimbursement wins, and the two tracks are now converging on a tight calendar. The medtech heavyweight's stock closed Friday at EUR 76.72, down 0.3% on the day, a modest move that masks a softer stretch — the shares have shed 3.6% over the past 30 days, with 2.2% of that decline coming since the MiniMed spinoff was set in motion roughly three weeks ago.

MiniMed Swap Hits Its Pricing Window

The next formal step in the diabetes-unit separation is now scheduled. According to Nasdaq, the three-day pricing period for the MiniMed exchange offer opens October 5 and runs through October 7. The offer itself expires — barring extension or early termination — at midnight New York time on October 9.

The mechanics of the transaction have drawn scrutiny. Barron's reported that the offer lost some of its appeal after MiniMed shares weakened following the launch of the exchange. On the organizational side, MiniMed named Sheila Denton as chief legal officer and corporate secretary.

Management's rationale for the carve-out centers on sharpening the core: shedding businesses with lower synergy to the rest of the medtech portfolio is meant to free up resources for research and launches in higher-margin segments. The market's reception around the transaction has nonetheless made the immediate backdrop more difficult. Medtronic's overall market capitalization stands at EUR 97.94 billion.

Four Clearances and a Breakthrough Tag

While the spinoff advances, Medtronic's clinical pipeline has been collecting regulatory green lights on both sides of the Atlantic. The Affera Prism-2 cardiac mapping software secured FDA clearance alongside the European CE mark, and the PulseSelect ProxBox adapter — equipped with proximity-detection software — also earned CE certification.

In peripheral vascular disease, the drug-coated IN.PACT BTK balloon catheter received Breakthrough Device designation from the FDA. Medtronic is preparing a randomized pivotal trial of roughly 400 patients to confirm the system's clinical performance.

Reimbursement Codes Lock In Two Therapies

Just as consequential as product approvals are the billing foundations that determine whether devices reach patients at scale. The American Medical Association granted new Category I CPT codes for two Medtronic systems: Altaviva, an implantable tibial neuromodulation device for urge incontinence, and Symplicity Spyral, the renal denervation system for hypertension.

The new codes replace the previous Category III transitional designations and take effect in January 2028. According to the company, they recognize the clinical evidence and growing physician adoption behind both therapies, effectively charting the reimbursement landscape for these procedures in the U.S. market for years to come.

Wall Street Support Holds, With a Nod From Fortune

Beyond the regulators, Fortune included Medtronic's Touch Surgery ecosystem and the Healthy Neighbor program from Medtronic LABS in its 2026 "Change the World" list.

Analyst sentiment remains steady. On Wednesday, TD Cowen reaffirmed its buy rating on the stock. For a company of Medtronic's scale, the path ahead hinges largely on how smoothly the new therapy systems transition into routine clinical practice — and on whether the MiniMed separation reaches its October finish line without further friction.